{"id":"c18231f6334a","type":"article","url":"https://hartvaat.nl/2018/07/31/antitrombotische-therapie-bij-af-met-oac-na-pci-aha-scientific-statement/","title":"Antitrombotische therapie bij AF met OAC na PCI: AHA scientific statement","title_en":"Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog"],"tags":[],"journal":"Circulation","doi":"10.1161/CIRCULATIONAHA.118.034722","source_url":"https://doi.org/10.1161/CIRCULATIONAHA.118.034722","authors":["Dominick J Angiolillo","Shaun G Goodman","Deepak L Bhatt","John W Eikelboom","Matthew J Price","David J Moliterno","Christopher P Cannon","Jean-Francois Tanguay","Christopher B Granger","Laura Mauri","David R Holmes","C Michael Gibson","David P Faxon"],"significance":8,"published":"2018-07-31","source_date":"2018-07-31","image":"","kennis":["https://hartvaat.nl/kennis/antistolling/dubbele-antistolling-indicaties/"],"congress":"","summary_en":"This AHA scientific statement on antithrombotic therapy in AF patients on anticoagulation undergoing PCI integrated evidence from PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS to provide practical guidance on dual versus triple antithrombotic strategies in this challenging clinical scenario.","created":"2026-07-03T10:27:23Z","updated":"2026-07-03T13:26:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"AHA scientific statement over antitrombotische therapie bij AF-patiënten op OAC die PCI ondergaan. Integreert PIONEER, RE-DUAL en AUGUSTUS in een praktijkkader.","abstract_original":"The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation represents a challenge in clinical practice. In 2016, an updated opinion of selected experts from the United States and Canada on the treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention was reported. After the 2016 North American consensus statement on the management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, results of pivotal clinical trials assessing the type of oral anticoagulant agent and the duration of antiplatelet treatment have been published. On the basis of these results, this focused update on the antithrombotic management of patients with atrial fibrillation undergoing percutaneous coronary intervention recommends that a non-vitamin K antagonist oral anticoagulant be preferred over a vitamin K antagonist as the oral anticoagulant of choice. Moreover, a double-therapy regimen (oral anticoagulant plus single antiplatelet therapy with a P2Y12 inhibitor) by the time of hospital discharge should be considered for most patients, whereas extending the use of aspirin beyond hospital discharge (ie, triple therapy) should be considered only for selected patients at high ischemic/thrombotic and low bleeding risks and for a limited period of time. The present document provides a focused updated on the rationale for the new expert consensus-derived recommendations on the antithrombotic management of patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention."}